GSK to grow Massachusetts work force with move from Maryland
The incoming employees at the biopharmaceutical giant will zero in on mRNA, structural biology, and viral vaccine research ...
GSK Class Action News: Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Class Action Involving GSK PLC
SAN DIEGO, CA / ACCESS Newswire / February 10, 2025 / Robbins LLP reminds stockholders that a class action was filed on ...
Shareholders that lost money on GSK plc(GSK) should contact Levi & Korsinsky about pending Class Action - GSK
NEW YORK, NY / ACCESS Newswire / February 11, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a ...
GSK Surges 8% After Bumping Its 2031 Outlook To North Of $50 Billion
GSK delivered a mixed fourth-quarter report Wednesday, but GSK stock surged on its long-term outlook for more than $50 ...
GSK launches $2.5 billion buyback, lifts sales target after stellar Q4
GSK launched a 2 billion pounds ($2.5 billion) share buyback on Wednesday and lifted its long-term sales target to nearly $50 ...
FierceBiotech6d
GSK drops one potential 'functional cure' for hep B as it goes all-in on bepirovirsen
GSK is prioritizing development of its hepatitis B treatment bepirovirsen as the pharma ends work on another potential ...
Business Wire1d
GSK INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that GSK plc Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has bee ...
GSK Launches $2.5 Billion Buyback, Raises Midterm Sales Outlook
The pharmaceutical giant targets an increase in core operating profit of between 6% and 8% in 2025, after cancer treatments ...
GSK is emerging from its long convalescence
Yet GSK is clearly healing from its multiple comorbidities — the worst of which was the (now largely resolved) legal overhang related to heartburn medicine Zantac. Chief executive Emma Walmsley also ...
GSK Stock Jumps on Long-Term Outlook Boost, $2.5B Share Buyback Plan
GSK Plc's U.S.-listed shares surged Wednesday after the pharmaceutical firm boosted its long-term outlook and launched a $2.5 ...
GSK, gold miners shares push Britain's FTSE 100 higher
UK's FTSE 100 firmed on Wednesday after two straight days of losses, buoyed by gains in shares of heavyweight GSK and gold ...
GSK launches £2bn buyback on strong HIV and cancer drugs sales
GSK launched a rare £2bn share buyback and raised its growth targets on the back of strong sales of speciality medicines, ...